UY25874A1 - Inhibidores de proteasas derivados de 4-amino-azepan-3-ona - Google Patents
Inhibidores de proteasas derivados de 4-amino-azepan-3-onaInfo
- Publication number
- UY25874A1 UY25874A1 UY25874A UY25874A UY25874A1 UY 25874 A1 UY25874 A1 UY 25874A1 UY 25874 A UY25874 A UY 25874A UY 25874 A UY25874 A UY 25874A UY 25874 A1 UY25874 A1 UY 25874A1
- Authority
- UY
- Uruguay
- Prior art keywords
- alkyl
- azepan
- compounds
- amino
- methyl
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 206010065687 Bone loss Diseases 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- AEZJMSICFGBQJC-BHWOMJMDSA-N (2S)-2-amino-N-(1-benzyl-3-oxoazepan-4-yl)-4-methylpentanamide Chemical compound C1C(=O)C(NC(=O)[C@@H](N)CC(C)C)CCCN1CC1=CC=CC=C1 AEZJMSICFGBQJC-BHWOMJMDSA-N 0.000 abstract 1
- QTLLOLTVQMFWDZ-UHFFFAOYSA-N 4-aminoazepan-3-one Chemical compound NC1CCCNCC1=O QTLLOLTVQMFWDZ-UHFFFAOYSA-N 0.000 abstract 1
- 102000004171 Cathepsin K Human genes 0.000 abstract 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- ZAIRIKJXUIZRPN-ADKAHSJRSA-N benzyl n-[(2s)-1-[(3-hydroxyazepan-4-yl)amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)NC1C(CNCCC1)O)C(=O)OCC1=CC=CC=C1 ZAIRIKJXUIZRPN-ADKAHSJRSA-N 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11363698P | 1998-12-23 | 1998-12-23 | |
| US16458199P | 1999-11-10 | 1999-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25874A1 true UY25874A1 (es) | 2001-08-27 |
Family
ID=26811293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25874A UY25874A1 (es) | 1998-12-23 | 1999-12-22 | Inhibidores de proteasas derivados de 4-amino-azepan-3-ona |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20020147188A1 (ja) |
| EP (1) | EP1158986A4 (ja) |
| JP (1) | JP2002533397A (ja) |
| KR (1) | KR100630986B1 (ja) |
| CN (1) | CN1253441C (ja) |
| AT (1) | ATE411294T1 (ja) |
| AU (1) | AU768565B2 (ja) |
| BR (1) | BR9916488A (ja) |
| CA (1) | CA2356671A1 (ja) |
| CZ (1) | CZ20012277A3 (ja) |
| DE (1) | DE69939752D1 (ja) |
| DZ (1) | DZ2977A1 (ja) |
| ES (1) | ES2315456T3 (ja) |
| GC (1) | GC0000178A (ja) |
| HK (1) | HK1043536A1 (ja) |
| HU (1) | HUP0104768A3 (ja) |
| IL (2) | IL143142A0 (ja) |
| NO (1) | NO318910B1 (ja) |
| NZ (1) | NZ511710A (ja) |
| PE (1) | PE20001340A1 (ja) |
| PL (1) | PL350132A1 (ja) |
| TR (1) | TR200101869T2 (ja) |
| UY (1) | UY25874A1 (ja) |
| WO (1) | WO2000038687A1 (ja) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1229912A4 (en) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| EP1229911A4 (en) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| WO2001034157A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| US6583137B1 (en) | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1351930A4 (en) * | 1999-11-10 | 2004-09-15 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| AU1474601A (en) * | 1999-11-10 | 2001-06-06 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1229915A4 (en) * | 1999-11-10 | 2003-05-14 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1231922A4 (en) * | 1999-11-10 | 2004-06-23 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| JP2003513924A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034599A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| CN1416346A (zh) * | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
| CO5280093A1 (es) * | 2000-04-18 | 2003-05-30 | Smithkline Beecham Corp | Metodos de tratamiento |
| CO5280088A1 (es) * | 2000-04-18 | 2003-05-30 | Smithkline Beecham Corp | Inhibidores de proteasa |
| SK17592002A3 (sk) * | 2000-06-14 | 2003-05-02 | Smithkline Beecham Corporation | 4-Amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty |
| WO2002017924A1 (en) * | 2000-09-01 | 2002-03-07 | Smithkline Beecham Corporation | Method of treatment |
| CN1635903A (zh) * | 2000-11-22 | 2005-07-06 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
| SI1370260T1 (sl) | 2001-02-20 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Azoli kot inhibitorji malonil-CoA dekarboksilaze, uporabni kot metabolični modulatorji |
| US7709510B2 (en) | 2001-02-20 | 2010-05-04 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators |
| WO2002092563A2 (en) * | 2001-05-17 | 2002-11-21 | Smithkline Beecham Corporation | Protease inhibitors |
| US6982263B2 (en) | 2001-06-08 | 2006-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Nitriles useful as reversible inhibitors of cysteine proteases |
| AU2003263738A1 (en) * | 2002-05-22 | 2003-12-02 | Smithkline Beecham Corporation | Protease inhibitors |
| US20050256105A1 (en) * | 2002-05-22 | 2005-11-17 | Jeong Jae U | Protease inhibitors |
| KR100962972B1 (ko) * | 2002-07-26 | 2010-06-09 | 주식회사유한양행 | 1-페닐피페리딘-3-온 유도체 및 그의 제조방법 |
| AU2003273697A1 (en) * | 2002-10-08 | 2004-05-04 | Merck Frosst Canada Ltd | 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis |
| SI3549936T1 (sl) | 2003-04-11 | 2021-09-30 | Ptc Therapeutics, Inc. | Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni |
| CA2533747C (en) * | 2003-08-01 | 2012-11-13 | Chugai Seiyaku Kabushiki Kaisha | Heterocyclic compounds useful as malonyl-coa decarboxylase inhibitors |
| ES2314491T3 (es) | 2003-08-01 | 2009-03-16 | Chugai Seiyaku Kabushiki Kaisha | Compuestos azol basados en cianoguanidina utiles como inhibidores de la manonil-coa descaraboxilasa. |
| CA2533749C (en) | 2003-08-01 | 2012-07-10 | Chugai Seiyaku Kabushiki Kaisha | Piperidine compounds useful as malonyl-coa decarboxylase inhibitors |
| CA2552726A1 (en) * | 2004-01-08 | 2005-07-21 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| EP1796793A4 (en) * | 2004-09-07 | 2009-08-05 | Smithkline Beecham Corp | NEW CONNECTIONS |
| WO2007012180A1 (en) * | 2005-07-26 | 2007-02-01 | Merck Frosst Canada Ltd. | Papain family cysteine protease inhibitors for the treatment of parasitic diseases |
| RU2462246C2 (ru) | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| BR112013029672A2 (pt) | 2011-05-16 | 2017-01-17 | Bayer Ip Gmbh | uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca |
| CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
| TWI636978B (zh) | 2014-03-06 | 2018-10-01 | 美商Ｐｔｃ治療公司 | １，２，４－二唑苯甲酸之鹽及醫藥組合物 |
| US10517853B2 (en) | 2015-10-30 | 2019-12-31 | Ptc Therapeutics, Inc. | Methods for treating epilepsy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1195287B (it) * | 1981-11-05 | 1988-10-12 | Ausonia Farma Srl | Derivato tiazolico,procedimento per la sua preparazione e relative composizioni farmaceutiche |
| JPH05140063A (ja) * | 1991-11-19 | 1993-06-08 | Suntory Ltd | ジペプチド誘導体及びそれを有効成分とする骨疾患の予防及び治療剤 |
| ATE171171T1 (de) * | 1992-12-25 | 1998-10-15 | Mitsubishi Chem Corp | Alpha-aminoketon derivate |
| CA2111930A1 (en) * | 1992-12-25 | 1994-06-26 | Ryoichi Ando | Aminoketone derivatives |
| JPH06199850A (ja) * | 1992-12-28 | 1994-07-19 | Tanabe Seiyaku Co Ltd | インドール含有ペプチド及びその製法 |
| EP0808839B1 (en) * | 1995-12-12 | 2001-05-23 | Taiho Pharmaceutical Co., Ltd. | Epoxysuccinamide derivatives or salts thereof, and drugs containing the same |
| US5902882A (en) * | 1996-04-17 | 1999-05-11 | Hoffmann-La Roche Inc. | Assymetric synthesis of azepines |
| DZ2285A1 (fr) * | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| US6107291A (en) * | 1997-12-19 | 2000-08-22 | Amgen Inc. | Azepine or larger medium ring derivatives and methods of use |
| EP1229915A4 (en) * | 1999-11-10 | 2003-05-14 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| WO2001034158A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1229912A4 (en) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| EP1351930A4 (en) * | 1999-11-10 | 2004-09-15 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| AU1474601A (en) * | 1999-11-10 | 2001-06-06 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034599A1 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| WO2001034565A2 (en) * | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
| US6583137B1 (en) * | 1999-11-10 | 2003-06-24 | Smithkline Beecham Corporation | Protease inhibitors |
| JP2003513924A (ja) * | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | プロテア−ゼ阻害剤 |
| EP1229911A4 (en) * | 1999-11-10 | 2003-05-07 | Smithkline Beecham Corp | PROTEASE INHIBITORS |
| NL1013996C2 (nl) * | 1999-12-30 | 2001-07-03 | Innas Free Piston Bv | Vrijezuiger aggregaat voor opwekken van hydraulische energie. |
-
1999
- 1999-12-21 CN CNB998150932A patent/CN1253441C/zh not_active Expired - Fee Related
- 1999-12-21 CA CA002356671A patent/CA2356671A1/en not_active Abandoned
- 1999-12-21 PL PL99350132A patent/PL350132A1/xx not_active Application Discontinuation
- 1999-12-21 DE DE69939752T patent/DE69939752D1/de not_active Expired - Lifetime
- 1999-12-21 AU AU19411/00A patent/AU768565B2/en not_active Ceased
- 1999-12-21 AT AT03076211T patent/ATE411294T1/de not_active IP Right Cessation
- 1999-12-21 BR BR9916488-4A patent/BR9916488A/pt not_active IP Right Cessation
- 1999-12-21 JP JP2000590640A patent/JP2002533397A/ja active Pending
- 1999-12-21 ES ES03076211T patent/ES2315456T3/es not_active Expired - Lifetime
- 1999-12-21 CZ CZ20012277A patent/CZ20012277A3/cs unknown
- 1999-12-21 TR TR2001/01869T patent/TR200101869T2/xx unknown
- 1999-12-21 EP EP99963112A patent/EP1158986A4/en not_active Withdrawn
- 1999-12-21 IL IL14314299A patent/IL143142A0/xx active IP Right Grant
- 1999-12-21 WO PCT/US1999/030730 patent/WO2000038687A1/en active IP Right Grant
- 1999-12-21 KR KR1020017007989A patent/KR100630986B1/ko not_active IP Right Cessation
- 1999-12-21 NZ NZ511710A patent/NZ511710A/en unknown
- 1999-12-21 HU HU0104768A patent/HUP0104768A3/hu unknown
- 1999-12-22 DZ DZ990277A patent/DZ2977A1/xx active
- 1999-12-22 GC GCP1999461 patent/GC0000178A/en active
- 1999-12-22 UY UY25874A patent/UY25874A1/es not_active Application Discontinuation
- 1999-12-23 PE PE1999001312A patent/PE20001340A1/es not_active Application Discontinuation
-
2001
- 2001-05-14 IL IL143142A patent/IL143142A/en not_active IP Right Cessation
- 2001-06-22 NO NO20013124A patent/NO318910B1/no unknown
-
2002
- 2002-02-13 US US10/074,940 patent/US20020147188A1/en not_active Abandoned
- 2002-05-13 HK HK02103610.2A patent/HK1043536A1/zh unknown
-
2003
- 2003-04-01 US US10/404,142 patent/US20030225061A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2356671A1 (en) | 2000-07-06 |
| EP1158986A4 (en) | 2002-03-27 |
| DE69939752D1 (de) | 2008-11-27 |
| US20020147188A1 (en) | 2002-10-10 |
| NO20013124D0 (no) | 2001-06-22 |
| JP2002533397A (ja) | 2002-10-08 |
| ATE411294T1 (de) | 2008-10-15 |
| PE20001340A1 (es) | 2001-01-28 |
| KR100630986B1 (ko) | 2006-10-09 |
| BR9916488A (pt) | 2001-10-09 |
| ES2315456T3 (es) | 2009-04-01 |
| NO318910B1 (no) | 2005-05-23 |
| CN1350458A (zh) | 2002-05-22 |
| PL350132A1 (en) | 2002-11-04 |
| NO20013124L (no) | 2001-06-22 |
| CN1253441C (zh) | 2006-04-26 |
| AU768565B2 (en) | 2003-12-18 |
| IL143142A (en) | 2006-08-20 |
| HUP0104768A2 (hu) | 2002-04-29 |
| AU1941100A (en) | 2000-07-31 |
| HK1043536A1 (zh) | 2002-09-20 |
| HUP0104768A3 (en) | 2002-05-28 |
| NZ511710A (en) | 2003-12-19 |
| US20030225061A1 (en) | 2003-12-04 |
| GC0000178A (en) | 2006-03-29 |
| EP1158986A1 (en) | 2001-12-05 |
| KR20010089677A (ko) | 2001-10-08 |
| CZ20012277A3 (cs) | 2001-11-14 |
| DZ2977A1 (fr) | 2004-03-15 |
| WO2000038687A1 (en) | 2000-07-06 |
| IL143142A0 (en) | 2002-04-21 |
| TR200101869T2 (tr) | 2002-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25874A1 (es) | Inhibidores de proteasas derivados de 4-amino-azepan-3-ona | |
| US4177290A (en) | Acetamide derivatives | |
| AR032877A1 (es) | Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos | |
| US4151300A (en) | Acetohydroxamic acids | |
| LU90836I2 (fr) | Acide zol-dronique et ses sels pharmaceutiquement acceptables | |
| US4994460A (en) | Agents for treatment of brain ischemia | |
| NO20013254D0 (no) | Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem | |
| NO20024217D0 (no) | 1,5-benzotiazepiner og deres anvendelse som hypolipidmidler | |
| SE0103046D0 (sv) | Kristallin bas av citalopram | |
| UY24409A1 (es) | Inhibidores de la matriz metaloproteasa | |
| EA009052B1 (ru) | Производные диарилсульфидов, способ их получения и промежуточные соединения | |
| PE20040907A1 (es) | Derivados de anilinopirazol | |
| UY24429A1 (es) | Acetidinas | |
| KR870004955A (ko) | 다양한 n-치환된 3-피페리딘카복실산 또는 n-치환된 3-피리딘카복실산 및 당해 유도체 | |
| EP1342720A2 (en) | Epoxysuccinamide derivatives | |
| RU2203661C2 (ru) | Новые серосодержащие производные с амидной связью, способ их получения, их применение в качестве медикаментов и фармацевтические композиции | |
| CA2417190A1 (en) | New beta-amyloid inhibitors, processes for preparing them and their use as pharmaceutical compositions | |
| AR041188A1 (es) | Compuestos derivados de indolinona sustituidos en posicion 6, su preparacion y su uso para preparar medicamentos | |
| EA200300018A1 (ru) | Ингибиторы протеаз | |
| UY24697A1 (es) | Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa | |
| ES2361343T3 (es) | Procedimiento para obtener n-(difenilmetil)piperazinas. | |
| UY25469A1 (es) | Procedimiento para preparar sulfonamidas | |
| US7989623B2 (en) | Process for making n-(diphenylmethyl)piperazines | |
| AR007101A1 (es) | Derivados de acido 4-arilbutirico sustituido como inhibidores de la metaloproteasa de matriz | |
| WO1994002473A1 (fr) | Derives de la n-cycloalkylpiperazine, procedes d'obtention et compositions pharmaceutiques les contenant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20090323 |